

## *SIL declares net sale YTD growth as -2% and Profit from Operations growth as +6% vs previous year*

**Mumbai, August 1<sup>st</sup>, 2025.** Sanofi India Limited (SIL) announced its financial results for the quarter ended June 30, 2025. The Company recorded a 9% decline in net sales on a comparable basis of continuing business.

In the **Domestic market**, the successful launch of Soliqua<sup>®</sup>, our premium diabetes treatment for the premix segment, continues to gain momentum, reinforcing our comprehensive diabetes portfolio. Toujeo<sup>®</sup> maintained strong performance with high single-digit growth.

Our strategic partnerships in Cardiovascular (CV) and Central Nervous System (CNS) segments have established a solid foundation, meeting expectations for market reach expansion and business acceleration.

**Export sales** were affected by non-recurring CHC product sales from 2024 and the planned discontinuation of the Zentiva portfolio.

For the year-to-date period ended June 2025, the Company achieved a 6% increase in operating profit (\*). This improvement stems from our focused approach to cost optimization and enhanced operational efficiencies.

The Company continues to transform while making significant progress in its India strategy through targeted market initiatives, operational excellence, and innovation advancement.

(\*): Operating profit = Revenue from operations – Total expenses

***Rachid Ayari***

Whole Time Director and Chief Financial Officer

*"During this transformative year for our company, our insulin portfolio has demonstrated robust growth, led by Toujeo<sup>®</sup> and the successful introduction of Soliqua<sup>®</sup> - our premium diabetes solution for the premix segment. Our strategic partnerships have effectively expanded our reach to healthcare professionals in both CV (Cardiovascular) and CNS (Central Nervous System) therapeutic areas, meeting our planned objectives. Moving forward, we remain committed to enhancing operational efficiency while broadening access to both our established products and innovative therapies across India."*

### ***Sanofi in India***

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from

the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its four global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices since 2019, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: [www.sanofi.com/en/in](http://www.sanofi.com/en/in), [LinkedIn](#) and [Twitter](#).

*Media Relations*

**Vinifer Gandhi** | [vinifer.gandhi@sanofi.com](mailto:vinifer.gandhi@sanofi.com)